Frank R Jones

This inventor holds 26 USPTO granted patents and 11 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Vaccine Development. Top assignees: Etubics Corporation, Imre Corporation, Cypress Bioscience, Inc.. Active years: 1989-2025.

USPTO Granted Patents = 26 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 9)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 2.6

ph-index = 8

Forward Citations = 164(Granted Patents)

Location History:

Sumter, SC (US) (1996)
Edmonds, WA (US) (1989 - 1998)
Ellensburg, WA (US) (2012 - 2022)
Seattle, WA (US) (2017 - 2023)

Company Filing History:

Cypress Bioscience, Inc.

patents

where one patent can have more than one assignee

Years Active: 1989-2025

Loading Chart...

Areas of Expertise:

Adenovirus Vector

Breast Cancer Vaccines

HPV Vaccines

Combination Immunotherapy

Tumor Vaccination

Alphavirus Vaccination

Flavivirus Vaccination

IL-15 Superagonists

Replication Defective Vector

Ebola Virus Glycoprotein

Rheumatoid Arthritis Treatment

HIV Treatment

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12370250 - Methods and compositions for producing an adenovirus vector for use with multiple vaccinations (2025-07-29),

2. 11826417 - Methods and compositions for producing an adenovirus vector for use with multiple vaccinations (2023-11-28),

3. 11529408 - Methods and compositions for producing an adenovirus vector for use with multiple vaccinations (2022-12-20),

4. 11504423 - Methods and compositions for producing an adenovirus vector for use with multiple vaccinations (2022-11-22),

5. 11389521 - Methods and compositions for producing an adenovirus vector for use with multiple vaccinations (2022-07-19),

6. 11376316 - Breast cancer vaccines and methods of use thereof (2022-07-05),

7. 11369673 - HPV vaccines and methods of use thereof (2022-06-28),

8. 11352642 - Methods and compositions for combination immunotherapy (2022-06-07),

9. 11344613 - Sequential administration of a replication defective adenovirus vector in vaccination protocols (2022-05-31),

10. 11304998 - Combination immunotherapies comprising IL-15 superagonists (2022-04-19),

11. 11149087 - Methods and compositions for combination immunotherapy (2021-10-19),

12. 11116827 - Compositions and methods for tumor vaccination and immunotherapy involving HER antigens (2021-09-14),

13. 11104916 - Compositions and methods for alphavirus vaccination (2021-08-31),

14. 11020467 - Combination immunotherapies comprising IL-15 superagonists (2021-06-01),

15. 10835596 - Compositions and methods for flavivirus vaccination (2020-11-17),

Title: Innovations in Vaccination: The Contributions of Frank R Jones

Introduction

Frank R Jones, based in Seattle, WA, is an accomplished inventor renowned for his significant contributions to the field of immunology and vaccine development. With a remarkable portfolio of 24 patents, Jones has been at the forefront of innovative technologies that enhance vaccination strategies, particularly utilizing adenovirus vectors.

Latest Patents

Among his latest patents are methods and compositions for producing an adenovirus vector designed for use with multiple vaccinations. These methods focus on generating immune responses using adenovirus vectors that allow for repeated vaccinations with the same vector, catering to individuals who may have existing immunity to adenovirus. This innovation is poised to make a considerable impact on vaccination efficacy and accessibility.

Career Highlights

Throughout his career, Frank R Jones has played pivotal roles in two notable companies: Etubics Corporation and Imre Corporation. His work at these organizations has furthered research into vaccine development, solidifying his reputation as a key innovator in this critical field.

Collaborations

Jones has also collaborated with esteemed professionals such as Joseph P Balint and Elizabeth Gabitzsch. These partnerships have fostered a productive environment for research and development, leading to advancements in the technologies surrounding adenovirus-based vaccines.

Conclusion

Frank R Jones exemplifies the spirit of innovation in the realm of vaccine development. With his extensive patent portfolio and collaborative efforts, he continues to pave the way for groundbreaking advancements that have the potential to transform public health and improve vaccination strategies worldwide.